Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2021 | PANGEA: personalized treatment strategy for patients with metastatic gastroesophageal adenocarcinoma

Daniel Catenacci, MD, University of Chicago, Chicago, IL, outlines the findings of a Phase II study evalating individualized treatment strategies for patients with metastatic gastroesophageal adenocarcinoma. Individually optimizing chemotherapy, biomarker profiling, and matching of targeted therapies resuled in improved outcomes when compared to historical controls. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Daniel Catenacci, MD has received support/funding from Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Tempus, Guardant Health, Archer, and Natera.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.